{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:50:51Z","timestamp":1787763051339,"version":"build-2784847793"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p><jats:bold>Objects:<\/jats:bold> This study was intended to find out more about the clinical characterizations of patients carrying transthyretin (TTR) E61K (p.Glu81Lys) gene mutation and the biochemical characterization of this mutant protein.<\/jats:p><jats:p><jats:bold>Materials and methods:<\/jats:bold> Five patients who had been diagnosed with hereditary transthyretin amyloidosis and two asymptomatic carriers carrying TTR E61K gene mutation were reported. Biochemical and biophysical tests were conducted to observe the thermodynamic and kinetic stability. Fibril formation tests measured by turbidity assay were performed to explore the pathogenicity of this mutation. Kinetic stabilizer responsiveness was measured to determine the inhibitory effect on protein aggregation.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The average age of onset for the five patients was 62 years, and the course of the disease ranged from 2 to 10 years. Cardiac disease was prominent in this group of patients. Nerve pathology revealed a mildly to moderately reduced myelinated fiber density and muscle pathology showed predominant neurogenic impairment accompanied by possible myogenic impairment. E61K-TTR was characterized as a kinetically destabilized protein compared to WT-TTR but its thermodynamic stability was not compromised. In addition, the subunit exchange of E61K with WT-TTR further destabilized the heterozygous tetramer. Meanwhile, the E61K:WT heterozygous tetramer exhibited a poor response to kinetic stabilizers in the fibril formation assay. Finally, the serum TTR tetramer concentration was low in E61K-TTR symptomatic patients and in one asymptomatic gene carrier. Vyndamax (Tafamidis) could increase the TTR tetramer concentration.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Patients with E61K mutation tended to be late-onset. The concentration of TTR tetramer in the serum might serve as a biomarker to monitor disease progress, therapeutic window time, and therapeutic response to TTR kinetic stabilizer drugs.<\/jats:p>","DOI":"10.3389\/fnmol.2022.1003303","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:48:08Z","timestamp":1665553688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by E61K mutation"],"prefix":"10.3389","volume":"15","author":[{"given":"Xujun","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/13506129.2010.483118","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/acn3.51328","article-title":"Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study","volume":"8","author":"Du","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"fcz032","DOI":"10.1093\/braincomms\/fcz032","article-title":"Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy","volume":"1","author":"Fernandes","year":"2019","journal-title":"Brain Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstr\u00f6m","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13023-019-1235-x","article-title":"Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy","volume":"14","author":"He","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/jmg.2005.033720","article-title":"Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcome","volume":"42","author":"Holmgren","year":"2005","journal-title":"J. Med. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12883-017-0957-4","article-title":"Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese","volume":"17","author":"Hsu","year":"2017","journal-title":"BMC Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF00220559","article-title":"Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement","volume":"89","author":"Jacobson","year":"1992","journal-title":"Hum. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","article-title":"The amino acid sequence of human plasma prealbumin","volume":"249","author":"Kanda","year":"1974","journal-title":"J. Biol. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1081\/MA-120017258","article-title":"Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy","volume":"150","author":"Kohno","year":"1997","journal-title":"Am. J. Pathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.wnl.0000132966.36437.12","article-title":"Pathology of early- vs. late-onset TTR Met30 familial amyloid polyneuropathy","volume":"63","author":"Koike","year":"2004","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","article-title":"Tafamidis: a review in transthyretin amyloidosis with polyneuropathy","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13560","DOI":"10.1021\/bi991021c","article-title":"The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions","volume":"38","author":"Lashuel","year":"1999","journal-title":"Biochemistry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/ene.13448","article-title":"Characterization of isolated amyloid myopathy","volume":"24","author":"Liewluck","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/13506129.2019.1582479","article-title":"Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy","volume":"26","author":"Low","year":"2019","journal-title":"Amyloid"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.7754382","article-title":"Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein","volume":"268","author":"Monaco","year":"1995","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/13506120109007355","article-title":"Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene","volume":"8","author":"Munar-Qu\u00e9s","year":"2001","journal-title":"Amyloid"},{"key":"B26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2017.08.017","article-title":"Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation","volume":"381","author":"Murakami","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.brainres.2010.06.017","article-title":"The transthyretin gene is expressed in Schwann cells of peripheral nerves","volume":"1348","author":"Murakami","year":"2010","journal-title":"Brain Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/jnc.15162","article-title":"A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy","volume":"156","author":"Murakami","year":"2021","journal-title":"J. Neurochem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2018.04.003","article-title":"Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant","volume":"390","author":"Nakano","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"key":"B31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/13506120902879335","article-title":"Cardiomyopathy in a Japanese family with the Glu61Lys transthyretin variant: a new phenotype","volume":"16","author":"Noto","year":"2009","journal-title":"Amyloid"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"key":"B34","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/S0021-9258(18)93118-2","article-title":"The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex","volume":"244","author":"Raz","year":"1969","journal-title":"J. Biol. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1073\/pnas.0503219102","article-title":"Transthyretin constitutes a functional component in pancreatic \u03b2-cell stimulus-secretion coupling","volume":"102","author":"Refai","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1021\/bi500739q","article-title":"Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case","volume":"53","author":"Robinson","year":"2014","journal-title":"Biochemistry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/pro.289","article-title":"Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations","volume":"19","author":"Rodrigues","year":"2010","journal-title":"Protein Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1006\/bbrc.1993.1933","article-title":"A basic transthyretin variant (Glu61\u2013>Lys) causes familial amyloidotic polyneuropathy: protein and DNA sequencing and PCR-induced mutation restriction analysis","volume":"194","author":"Shiomi","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"Soprano","year":"1985","journal-title":"J. Biol. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/34.7.3458812","article-title":"Synthesis of transthyretin (pre-albumin) mRNA in choroid plexus epithelial cells, localized by in situ hybridization in rat brain","volume":"34","author":"Stauder","year":"1986","journal-title":"J. Histochem. Cytochem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13506120701464396","article-title":"In vivo stabilization of mutant human transthyretin in transgenic mice","volume":"14","author":"Tagoe","year":"2007","journal-title":"Amyloid"},{"key":"B44","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mus.21028","article-title":"Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy","volume":"37","author":"Tojo","year":"2008","journal-title":"Muscle Nerve"},{"key":"B45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/13506129.2015.1104661","article-title":"Two brothers homozygous for the TTR V30M both presenting with a phenotype dominated by central nervous complications","volume":"22","author":"Uchida","year":"2015","journal-title":"Amyloid"},{"key":"B46","doi-asserted-by":"publisher","first-page":"900313","DOI":"10.3389\/fcvm.2022.900313","article-title":"Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in south China","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/13506120410001688581","article-title":"Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene","volume":"11","author":"Yoshinaga","year":"2004","journal-title":"Amyloid"},{"key":"B48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jocn.2018.10.040","article-title":"Familial amyloid polyneuropathy with chronic paroxysmal dry cough in Mainland China: a Chinese family with a proven heterozygous missense mutation c.349G>T in the transthyretin gene","volume":"60","author":"Yuan","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1021\/acschemneuro.0c00338","article-title":"Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis","volume":"11","author":"Zhou","year":"2020","journal-title":"ACS Chem. Neurosci."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2022.1003303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T05:48:12Z","timestamp":1665553692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2022.1003303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":47,"alternative-id":["10.3389\/fnmol.2022.1003303"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2022.1003303","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"article-number":"1003303"}}